Results 151 to 160 of about 11,335 (243)

Unlocking the therapeutic potential of HDAC8-degrading PROTACs: progress, challenges, and future directions. [PDF]

RSC Med Chem
Banerjee S, Adhikari N, Ghosh B.
europepmc   +1 more source

Chemoproteomic-Driven Discovery of Covalent PROTACs [PDF]

Biochemistry, 2019
Yiqing Zhou, Youli Xiao
openaire   +2 more sources

Tumor microenvironment-activated ferritin nanovector enables enhanced tumor delivery of KRAS^G12C inhibitors and degraders. [PDF]

Front Cell Dev Biol
Abbinantefina AP, Tito C, Masciarelli S, Tisci G, Sortoluzzi S, Ceci P, Falvo E, Exertier C, Troilo F, Petrozza V, Mai A, Rotili D, Fazi F, Colotti G.   +13 more
europepmc   +1 more source

Nano-PROTACs for precision medicine: engineering strategies for enhanced targeting and potency. [PDF]

J Nanobiotechnology
Yang X, Wang D, Li C, Zhang Y, Yang J, Liu M, Xing D, Jiang W, Xu S, Wang C.   +9 more
europepmc   +1 more source

PROTAC-based protein degradation: a window of opportunity for melanoma therapy. [PDF]

J Biomed Sci
Gentile G, D'Aguanno S, Di Martile M, Petricca A, Valentini E, Scalera S, Del Bufalo D.   +6 more
europepmc   +1 more source

Computational Modeling of PROTAC Ternary Complexes as Ensembles Using SILCS-xTAC. [PDF]

J Chem Inf Model
Nordquist EB, Zhao M, Yu W, MacKerell AD.   +3 more
europepmc   +1 more source

Proteolysis Targeting Chimera Loaded Extracellular Vesicles for Developing Triple Negative Breast Cancer Treatment. [PDF]

J Extracell Vesicles
Erwin N, De U, Xiao Y, Wang L, Maharjan CK, Pan X, Zuo D, Awasthee N, Zheng G, Liao D, Zhang W, He M.   +11 more
europepmc   +1 more source

Correction to "DNA-Programmable Protein Degradation: Dynamic Control of Proteolysis-Targeting Chimera Activity via DNA Hybridization and Strand Displacement". [PDF]

JACS Au
Kashyap D, Haider S, Milne TA, Booth MJ.
europepmc   +1 more source

Advancing PROTAC Discovery Through Artificial Intelligence: Opportunities, Challenges, and Future Directions. [PDF]

Pharmaceuticals (Basel)
Park KS, Jeon M.
europepmc   +1 more source

A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model. [PDF]

Oncogene
Takahashi R, Yamamoto K, Toya H, Shoji H, Kawanishi K, Momosaki K, Yabe M, Takashima K, Muromoto R, Ichikawa S, Matsuda T, Kitai Y.   +11 more
europepmc   +1 more source